TORCHLIGHT

NCT04085276 📎

Regimen

Experimental
Toripalimab 240 mg IV q3w + nab-paclitaxel 125 mg/m2 IV d1, d8 q3w.
Control
Placebo + nab-paclitaxel 125 mg/m2 IV d1, d8 q3w.

Population

Previously untreated or taxane-naive metastatic or recurrent triple-negative breast cancer; stratified by PD-L1 CPS status (>=1 vs <1).

Key finding

TORCHLIGHT showed toripalimab + nab-paclitaxel significantly prolonged PFS in PD-L1 CPS>=1 mTNBC vs chemo alone. NMPA approved toripalimab for 1L PD-L1+ mTNBC in 2023. First positive Chinese IO+chemo phase 3 in TNBC, mirroring KEYNOTE-355.

Source: PMID 38191615

Timeline

  • Publication: 2024 Jan

Guideline citations

  • NCCN BREAST